China SXT Pharmaceuticals (SXTC) Enterprise Value (2018 - 2025)
China SXT Pharmaceuticals (SXTC) has 8 years of Enterprise Value data on record, last reported at -$18.1 million in Q1 2025.
- For Q1 2025, Enterprise Value fell 50.11% year-over-year to -$18.1 million; the TTM value through Mar 2025 reached -$18.1 million, down 50.11%, while the annual FY2025 figure was -$18.1 million, 50.11% down from the prior year.
- Enterprise Value reached -$18.1 million in Q1 2025 per SXTC's latest filing, down from -$12.1 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$45297.0 in Q1 2022 and bottomed at -$18.1 million in Q1 2025.
- Average Enterprise Value over 5 years is -$12.2 million, with a median of -$13.4 million recorded in 2021.
- Peak YoY movement for Enterprise Value: soared 99.66% in 2022, then tumbled 38243.55% in 2023.
- A 5-year view of Enterprise Value shows it stood at -$13.4 million in 2021, then skyrocketed by 99.66% to -$45297.0 in 2022, then crashed by 38243.55% to -$17.4 million in 2023, then skyrocketed by 30.46% to -$12.1 million in 2024, then tumbled by 50.11% to -$18.1 million in 2025.
- Per Business Quant database, its latest 3 readings for Enterprise Value were -$18.1 million in Q1 2025, -$12.1 million in Q1 2024, and -$17.4 million in Q1 2023.